Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any congenital disorder of glycosylation in which the cause of the disease is a mutation in ALG10.
Biomarker and diagnostic research for ALG10-congenital disorder of glycosylation has been reported in the published literature.
No clinical trials have been registered for ALG10-congenital disorder of glycosylation.
264 publications have been identified in PubMed for ALG10-congenital disorder of glycosylation. Research spans Review / Meta-Analysis (43%), Basic Science / Preclinical (43%), and Diagnostic / Biomarker (5%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 114 | 43% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 4:38 PM UTC
Common questions about ALG10-congenital disorder of glycosylation
Laboratory research
113 |
43% |
Testing and diagnosis research | 12 | 5% |
Disease patterns and progression | 12 | 5% |
Patient case studies | 5 | 2% |
New treatment approaches | 5 | 2% |
Clinical study results | 3 | 1% |
He M (2026). [PMID: 41685570](https://pubmed.ncbi.nlm.nih.gov/41685570/). *Int J Mol Med*. [Review / Meta-Analysis]
Li P (2026). [PMID: 41316688](https://pubmed.ncbi.nlm.nih.gov/41316688/). *Allergy*. [Review / Meta-Analysis]
Toledo AG (2026). [PMID: 42059453](https://pubmed.ncbi.nlm.nih.gov/42059453/). *MAbs*. [Epidemiology / Natural History]
Zhu N (2026). [PMID: 41177858](https://pubmed.ncbi.nlm.nih.gov/41177858/). *Sci China Life Sci*. [Epidemiology / Natural History]
Liu J (2026). [PMID: 42012463](https://pubmed.ncbi.nlm.nih.gov/42012463/). *FASEB J*. [Review / Meta-Analysis]
Johannes L (2026). [PMID: 41173705](https://pubmed.ncbi.nlm.nih.gov/41173705/). *Trends Cell Biol*. [Review / Meta-Analysis]
Jiang S (2026). [PMID: 41698153](https://pubmed.ncbi.nlm.nih.gov/41698153/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Yi L (2026). [PMID: 41264770](https://pubmed.ncbi.nlm.nih.gov/41264770/). *Protein Cell*. [Review / Meta-Analysis]
Harada Y (2026). [PMID: 41895537](https://pubmed.ncbi.nlm.nih.gov/41895537/). *Biochim Biophys Acta Gen Subj*. [Review / Meta-Analysis]
Ünsal Y (2026). [PMID: 39975416](https://pubmed.ncbi.nlm.nih.gov/39975416/). *J Clin Res Pediatr Endocrinol*. [Review / Meta-Analysis]
AI-curated news mentioning ALG10-congenital disorder of glycosylation
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.